For the roughly 30-40% of obstructive sleep apnea patients who genuinely can’t tolerate CPAP, the conversation used to dead-end pretty fast. There was surgery — sometimes aggressive, sometimes disappointing — and oral appliances that worked for mild cases but struggled with moderate-to-severe disease. Then hypoglossal nerve stimulation came along and changed the calculus entirely.

What Hypoglossal Nerve Stimulation Actually Is

The concept is straightforward, even if the engineering behind it isn’t. A small pulse generator gets implanted under the skin in the upper chest — think of it like a pacemaker, but for your tongue. A sensing lead monitors your breathing pattern, and a stimulation lead wraps around the hypoglossal nerve, which controls tongue movement. When you inhale during sleep, the device delivers a mild electrical signal that pushes the tongue forward, preventing it from collapsing back and blocking your airway.

The brand name most people know is Inspire, which received FDA approval back in 2014 and has since been implanted in over 80,000 patients worldwide.

The Implant Procedure

Surgery typically takes about two hours under general anaesthesia. The surgeon makes three small incisions: one below the jawline to access the hypoglossal nerve, one on the chest wall for the pulse generator, and one along the ribcage for the breathing sensor. Most patients go home the same day or the following morning.

Here’s a detail that surprises people: the device isn’t activated immediately. You’ll wait about a month for the surgical sites to heal. Then you come back to the clinic for the initial titration, where we turn it on and start dialling in the right stimulation level. It’s a process, not a single appointment — expect a few follow-up visits to get the settings optimised.

You control it with a small remote. Click it on before bed, click it off when you wake up. That’s the nightly routine.

Who’s a Good Candidate?

Not everyone qualifies, and the screening criteria matter. According to the American Academy of Sleep Medicine, current guidelines generally require:

• Moderate-to-severe obstructive sleep apnea (AHI between 15 and 65)
• Documented CPAP intolerance or failure
• BMI under 40 (though some centres are pushing this boundary with newer data)
• No significant concentric collapse at the palatal level (confirmed by drug-induced sleep endoscopy, or DISE)

That last point is critical. During DISE, a doctor sedates you lightly and uses a flexible scope to watch your airway collapse in real time. If your soft palate collapses in a complete circular pattern rather than front-to-back, the stimulation won’t open the airway effectively. Roughly 25-30% of candidates get screened out at this stage.

What the Data Shows

The landmark STAR trial, published in the New England Journal of Medicine, followed patients for five years and reported a 79% reduction in AHI (apnea-hypopnea index) from baseline. The median AHI dropped from 29 events per hour to 6.2. Daytime sleepiness scores improved significantly, and bed partners reported major reductions in snoring.

More recent real-world data has largely confirmed these findings, though outcomes in clinical practice tend to be slightly less dramatic than in tightly controlled trials — which is normal for any medical intervention.

Patient satisfaction rates hover around 90%, which is remarkable for any sleep apnea therapy. Compare that to CPAP adherence rates of 50-60% at one year, and you see why this device generates so much interest.

Limitations and Honest Concerns

It’s not perfect. Here’s what I think patients should know upfront:

It’s still surgery. Complications are uncommon but real. Tongue weakness, infection, lead migration, and discomfort at the implant site all occur in a small percentage of cases. Most are manageable, but revision surgery is sometimes necessary.

It doesn’t cure sleep apnea. Turn the device off, and your apnea returns. You’re committing to nightly use for as long as you want the benefit.

Insurance coverage varies wildly. Most major insurers now cover it for patients who meet criteria, but prior authorisation can be a battle. Out-of-pocket costs without insurance can exceed $30,000-$50,000 depending on the facility.

Battery life is finite. The pulse generator battery lasts roughly 11 years, after which you’ll need a replacement procedure — simpler than the original surgery, but still a procedure.

The Broader Picture

Hypoglossal nerve stimulation represents a genuine shift in how we treat CPAP-intolerant patients with moderate-to-severe sleep apnea. It’s not for everyone, and it shouldn’t be positioned as the first-line alternative to CPAP — oral appliances, positional therapy, and weight management all have their place. But for the right patient, it fills a gap that was frustratingly empty for decades.

If you’re struggling with CPAP and wondering whether you might be a candidate, the starting point is a conversation with a board-certified sleep medicine physician who can walk you through screening. The path from evaluation to a functioning implant takes several months, so it’s worth starting that conversation sooner rather than later.

The technology is still evolving, too. Newer electrode designs, adaptive algorithms, and bilateral stimulation approaches are all in various stages of development. We’re likely only seeing the beginning of what neurostimulation can do for sleep-disordered breathing.